Markets & FinancePrivate Equity Firms Cut Deal Activity 75% While Biotech Bets Double Amid Global Market VolatilityViaNews Editorial Team•Feb 27, 2026
Pharmaceuticals & BiotechJapan's Nxera Pharma Highlights a Universal Biotech Dilemma: When a Thin Pipeline Means All-or-Nothing RiskViaNews Editorial Team•Feb 18, 2026
